Ligand Pharmaceuticals Inc. filings document the regulatory record for a Nasdaq-listed biopharmaceutical royalty aggregator with common stock trading under LGND. The company’s disclosures cover royalty portfolio economics, technology licenses, partner-product clinical and regulatory matters, operating results, milestone payments, commercial royalties, Captisol® material sales, and NITRICIL™ licensing.
Ligand’s SEC record also includes Form 8-K reports on material agreements, license-program rights, credit-agreement amendments, Regulation FD communications, capital-structure disclosures, and financial results. Proxy materials describe board matters, shareholder voting items, executive compensation, equity awards, and governance practices for the public company.
Ligand Pharmaceuticals Incorporated (LGND) completed its acquisition of XOMA Royalty Corporation on July 14, 2026, for a preliminary purchase price of $887.0 million. Consideration included $833.5 million in cash paid upon acquisition, including $691.7 million for XOMA Royalty common stock at $39.00 per share; the remaining $53.5 million related to XOMA equity awards. The acquired portfolio included seven commercial products, 14 late-stage development programs and more than 100 other assets in development.
For the third quarter, total revenues and income were $78.7 million, compared with $115.5 million a year earlier; royalties rose to $70.3 million from $46.6 million. The prior-year quarter included $53.1 million of income from the Pelthos transaction. Ligand recorded a $28.5 million net loss, versus $117.3 million net income, including a $35.7 million loss from changes in fair value of equity-method and other investments. For the first nine months, operating cash flow was $45.1 million, compared with $3.4 million. At September 30, 2026, cash and cash equivalents were $56.0 million and short-term investments were $391.4 million.
Ligand Pharmaceuticals Inc. director Jason M. Aryeh reported a proposed sale of 1,209 common shares, with an aggregate market value of $385,185.47 and an approximate sale date of October 30, 2026. The sale details name Morgan Stanley Smith Barney LLC Executive Financial Services. The shares are identified as restricted stock acquired from the issuer on June 5, 2026.
Ligand Pharmaceuticals Inc. (LGND) director Jason M. Aryeh reported a planned sale of 202 common shares through Charles Schwab & Co., Inc., with an aggregate market value of $64,738.00 and an approximate sale date of October 30, 2026. The notice lists the shares as acquired in an open-market purchase on March 13, 2019, with cash payment.
Ligand Pharmaceuticals Incorporated reported third-quarter 2026 royalty revenue of $70.3 million, up 51% year over year from $46.6 million; royalties were 89% of total revenues and income. Total revenues and income were $78.7 million, down 32% from $115.5 million, as the prior-year quarter included $53.1 million of Pelthos divestiture-related income; excluding that item, total revenues and income increased 26%. Captisol sales were $7.9 million versus $10.7 million.
GAAP results were a $28.5 million net loss, versus $117.3 million net income a year earlier; third-quarter results included $39.5 million of pre-tax investment losses. Adjusted net income was $57.5 million, down 10%, and adjusted earnings per diluted share were $2.67, down 14%. General and administrative expense was $72.6 million versus $28.4 million, reflecting XOMA transaction and integration costs, share-based compensation and higher employee-related costs. Ligand raised full-year 2026 adjusted diluted EPS guidance to $9.50–$9.75 from $9.00–$9.50 and reaffirmed revenue guidance.
Ligand Pharmaceuticals (LGND) Chief Legal Officer and Secretary Andrew Reardon exercised 340 employee stock options on October 2, 2026, at a $52.27 exercise price, acquiring 340 common shares; 29,104 options remained after the exercise. That day, he sold 5,000 common shares in six transactions under a written Rule 10b5-1 plan adopted June 4, 2026. Five sale blocks carried weighted-average prices of $302.5107 (833 shares), $303.5444 (1,976 shares), $304.5154 (1,535 shares), $306.1834 (404 shares), and $307.1911 (235 shares); another 17 shares were reported at $307.7400.
Ligand Pharmaceuticals Inc. director Martine Zimmermann had 115 shares withheld by the issuer on September 22, 2026, to pay tax liability arising from restricted stock unit settlement. The reported price was $298.50 per share, and Zimmermann’s direct holdings after the transaction were 3,782 shares. No Rule 10b5-1 plan is reported.
Ligand Pharmaceuticals Incorporated entered into a financing agreement with AvenCell Therapeutics for up to $47 million. Ligand committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales of all current and future AvenCell pipeline assets, with the royalty rate determined by the total amount ultimately funded.
The capital will be funded in four tranches: the first is payable at closing, and the remaining three are payable upon achievement of predetermined clinical milestones and other specified financing conditions. Ligand also committed up to $6 million in concomitant Series C financing. AvenCell’s AVC-201 is in a Phase 1b expansion trial for relapsed or refractory acute myeloid leukemia; AVC-203 is a Phase 1a program for B-cell malignancies.
Ligand Pharmaceuticals Incorporated (LGND) reported that it has acquired royalty and milestone payment rights related to Santen Pharmaceutical’s Ryjunea® from Sydnexis, Inc. for a $23 million upfront payment. The rights are tied to an existing license agreement between Sydnexis and Santen covering Europe, the Middle East and Africa.
Ligand will receive an ascending, tiered low-double-digit to high-teens royalty on Ryjunea net sales in EMEA, plus specified milestone payments, while Sydnexis retains commercial rights in the U.S. and other non-Santen territories. Ryjunea is a once-nightly 0.01% low-dose atropine eye drop approved by the European Commission in June 2025 and by the UK MHRA in October 2025 to slow progression of pediatric myopia. Ligand describes this as a differentiated addition to its royalty portfolio, noting Santen’s strategic focus on myopia and estimating a large addressable market, with Santen citing 14 million myopia patients in Europe in 2025.
LIGAND PHARMACEUTICALS INC (LGND) director Martine Zimmermann reported selling 1,200 shares of common stock on September 10, 2026 in an open market or private transaction at $285.00 per share. After this sale, Zimmermann directly holds 3,897 shares of LGND common stock, and no Rule 10b5-1 trading plan is reported.
LIGAND PHARMACEUTICALS INC (LGND) has a notice of proposed sale of common stock filed on behalf of director Martine Zimmermann under Rule 144. The notice covers 1,200 shares of common stock, with an aggregate market value of $342,000, to be sold through Morgan Stanley Smith Barney LLC on or about September 10, 2026 on NASDAQ.
The shares to be sold relate to restricted stock issued by the company, including 438 shares from a grant dated June 6, 2025 and 762 shares from a grant dated September 22, 2024. Shares outstanding are stated as 19,935,609, a baseline figure, not the amount being sold.